As the first original research drug in the field of diabetes in China, it has been recommended for meal injection and approved for the hypoglycemic intervention of T2DM (40), especially for patients with poor blood glucose control by metformin alone
Human and preclinical research There are currently no dedicated clinical studies evaluating GLOW as a three-peptide formulation
Suitability depends on factors such as BMI, medical history, existing health conditions and current medications rather than Hashimotos disease alone
Safety Endpoints in Research Multiple clinical studies have confirmed the safety of both L-citrulline and glutathione, with no significant adverse effects reported when used as directed: Hwang et al
INSIDER UPDATES Get expert wellness tips, treatment news, and curated content.
doi: 10.2147/DDDT.S470826